NBSE — NeuBase Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual cashflow statement for NeuBase Therapeutics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.

	2018 September 30th	2019 September 30th	2020 September 30th	2021 September 30th	2022 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-13.2	-27	-17.4	-25.4	-33.8
Depreciation
Amortisation
Non-Cash Items	5.41	23.4	5.91	5.77	3.82
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2.79	0.623	0.479	0.361	0.177
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Cash from Operating Activities	-9.49	-2.85	-10.7	-18.9	-29
Capital Expenditures	0	-0.509	-0.717	-1.44	-0.472
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.528	-0.176	0	-1.13	-0
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	0.528	-0.685	-0.717	-2.56	-0.472
Financing Cash Flow Items	—	-0.09	-0.35	-0.382	-0.148
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-0.086	13.6	33.1	42.3	-0.257
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-9.05	10.1	21.7	20.9	-29.7